To make the therapy safer and more adaptable, UChicago researchers developed a new “split” system called GA1CAR. This uses ...
As of April 2025, four CD19-directed chimeric antigen receptor (CAR)-T therapies and three CD20-targeting bispecific antibodies (BsAbs) have been US Food and Drug Administration (FDA) approved for the ...
Study sets stage for development of synthetic biosensors with custom-built sensing and responses for basic and translational cell engineering applications.
On February 13, Allogene Therapeutics published new long-term follow-up data on cemacabtagene ansegedleucel, showing the investigative allogeneic chimeric antigen receptor (CAR) T-cell therapy ...
Cancer immunotherapy, especially using T cells, is showing a lot of promise in treating blood cancers. Bioengineered T cells, ...
As of September 26, 2024, 33 CD19 CAR T-naïve patients with LBCL (median age, 66 years; median number of previous therapies, 3) received allogeneic CAR T cells. CAR T-cell expansion was observed ...
Chimeric antigen receptor (CAR) T cells targeting CD19 have transformed the treatment of B-cell cancers, but many patients do not have long-term remission. We designed an anti-CD19 enhanced (armored) ...
Immunotherapy has revolutionized cancer treatment by harnessing the power of T cells to attack tumors. But, even when these treatments are successful, scientists often struggle to understand exactly ...
Please provide your email address to receive an email when new articles are posted on . A “complete eradication” of B cells with chimeric antigen receptor T-cell therapy is responsible for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback